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Abstract 
Background: The influenza virus hemagglutinin is the major surface protein of the influenza A virus which is 
composed of HA1 and HA2 subunits. HA1 has an important role in  binding of virus to cells and designing 
neutralizing antibodies. Escherichia coli (E. coli) and Bacillus subtilis (B. subtilis) both are known as the most useful 
prokaryotic hosts to express recombinant proteins. The aim of this study was to clone and express recombinant HA1 
protein in E. coli and B. subtilis bacteria.  
Materials and Methods: HA1 gene was cloned into pET-28a vector and pHT43 shuttle vector and then, both 
transformed to E. coli. The recombinant plasmids were extracted and then transformed into the BL21 and WB600 as 
expressing hosts. After induction with isopropyl-β-d-thiogalactoside (IPTG), expressed recombinant protein was 
analyzed by SDS-PAGE. Finally, the expressed protein was confirmed by the Western blot.  
Results: HA1 gene was cloned into pET-28a vector and pHT43 shuttle vector and then, both transformed to E. coli. 
The recombinant plasmids were extracted and then transformed into the BL21 and WB600 as expressing hosts. After 
induction with isopropyl-β-d-thiogalactoside (IPTG), expressed recombinant protein was analyzed by SDS-PAGE. 
Finally, the expressed protein was confirmed by the Western blot.  
Conclusion: This study demonstrated a strategy for production and purification of recombinant protein in large 
scale to test as vaccine candidate against influenza and it’s potentially immunogenicity be assessed in animal models.        
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Influenza virus is a member of the 
Orthomyxoviridae family and has segmented 
negative single strand RNA genome that encodes 11 
proteins. Orthomyxoviridae family contains three 
genera of influenza viruses: influenza A, B and C. 
Influenza A (H3N2) virus is one of the human 
genotypes of influenza that causes seasonal epidemics 
(1). Historically, this virus has been responsible for 
1968 and 1969 pandemic (Hong Kong Flu) that killed 
34000 people just in USA (2). There are high rates of 
genetic shift and drift to generate various subtypes due 
to segmented viral genome of influenza and its RNA 
nature, and therefore, new strains are introduced each 
year which even may cause flu pandemics (3). This 
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fact makes the very important ability to produce 
vaccines, especially, when new vaccines shoud be 
produced in large scale, during short time. The outer 
surface of the virus has been covered with two 
antigenic glycoproteins: Haemagglutinin (HA) and 
Neuraminidase (NA) (4, 5). Haemagglutinin and 
Neuraminidase activities are critical for virus 
replication and influenza virus A can be categorize 
into subtypes based on  their antigenic diversity, so 
that at present, there are 16 known HA subtypes and 
9 known NA subtypes of influenza A virus (6). 
Haemagglutinin (HA) is the major surface 
glycoprotein in influenza A virus that is composed of 
two subunits: HA1 and HA2 (7). Since it is included 
the receptor binding sites, HA1 plays an important 
role in binding of virus to host cells (7). According to 
its presence in the community, Influenza A virus 
(H3N2) is always considered in the composition of 
the trivalent vaccines (8). Experimental evidence 
suggests that HA glycosylation may be important in 
folding and recognition of cell receptors, but it is not 
critical in immunogenicity and therefore, the 
immunogenic properties can be preserved even by its 
expression in prokaryotic systems (5). In other hand, 
prokaryotic system can be used to produce vaccines 
in large scale and during short times. Both E. coli and 
Bacillus subtilis are attractive hosts for the 
production of recombinant proteins (9).  
In this research, HA1 encoding sequence was 
cloned and expressed in E. coli and B. subtilis to 
assess produced proteins, a candidate vaccine against 
influenza A virus (H3N2).        
Methods 
Extraction and proliferation of HA1. The 
genome of influenza virus H3N2 (prepared by 
Pasteur Institute of IRAN) was extracted by 
PureLink Viral RNA/DNA mini kit (USA, 
Invitrogen). RNA was converted to cDNA by using 
RevertAiadTM H Minus M-MuLV reverse 
Transcriptase (Fermentas, Lithuania) and universal 
primers Uni12 according the following conditions: 
10 min at 25C and 60 min at 42C. 
The synthesized cDNA was used as a template 
and PCR reaction was performed by using High 
Fidelity Taq polymerase (Fermentase, Lithuania) to 
amplify HA1 gene with specific primers. Primers 
contained unique restriction sites for NheI (Forward) 
and SalI (Reverse) to facilitate cloning. Also, a stop 
codon was inserted at 5ˊ end of reverse primer. The 







The used conditions were: 95 Ċ for 3 min, 35 
cycles of (95Ċ 30s, 58Ċ 30s, and 72Ċ 1min) and 
final extension of 72 Ċ for 10min.  Then, PCR product 
was examined by electrophoresis on a 1% w/v agarose 
gel.   
Cloning of HA1 gene. First, the PCR product 
was ligated into pTZ57R/T vector (InsTAclone PCR 
Cloning kit, Fermentase, Lithuannia) based on TA 
cloning scheme and according manufacturer’s 
instructions. Following blue/white colony screening, 
recombinant colonies were confirmed by colony PCR, 
using M13 universal primers. Then, DNA plasmid 
Mini extraction kit (Bioneer, Korea) was used to 
isolate related plasmids from bacterial cells. Because 
incorporated sites of XbaI and SmaI, which were 
designed in primers, were not compatible buffer to 
cause digestion with adequate efficiency, digestion 
was performed by EcoRI/SalI that their restriction 
sites presented in pTZ5R/T, at both sides of HA1 
gene. Therefore, pTZ57R/T+HA1 was digested by 
using EcoRI/SalI to sub-clone in pET28a and was 
double digested by XbaI and SmaI in order to 
subcloning of HA1 in pHT43.  Also, EcoRI and SalI 
were used to digest pET-28a and XbaI and SmaI were 
used to digest pHT43 shuttle vector. Following 
electrophoresis of digested products, extraction of the 
digested vector and insert from agarose gel was 
performed using a gel extraction kit (Invitrogen, 
USA). Then, ligation was performed with T4 DNA 
ligase enzyme (Fermentase, Lithuania) and ligation 
products were transformed into DH5-α strain by 
CaCl2 method. Finally, transformant cells, containing 
pET-28a, were plated on LB agar with kanamycin (30 
μg/ml) and transformant cells, containing pHT43, 
were plated on LB agar with ampicillin (50 μg/ml) and 
incubated overnight at 37Ċ. Then, colony PCR was 
Cloning and prokaryotic expression of the globular head domain of hemagglutinin antigen (HA1) …                      Bidram et al. 
Vol 3, No 1,  Winter 2017 
3 
performed to identify recombinant colonies and 
finally recombination confirmed by enzymatic 
digestion. Resultant recombinant plasmids, pET-28a-
HA1 and pHT43-HA1, were extracted and 
transformed to expression strains, E.coli (BL21) by 
chemical method and to Bacillus Subtilis (WB600) 
by electroporation respectively. 
Expression. For protein expression, E. coli 
(BL21) cells containing pET-28a-HA1 were grown 
in 5ml LB broth supplemented with kanamycin (30 
μg/ml) and Bacillus Subtilis (WB600) cells 
containing pHT43-HA1 were incubated in 5ml LB 
broth supplemented with ampicillin (50 μg/ml) 
overnight at 37C. Then, 2ml of culture each were 
inoculated to 13 ml fresh mediums. When the OD600 
reached 0.7, expression was induced by adding 0.1 
mM IPTG to the cultures. No induced samples were 
harvested from the culture before induction (1 ml). 
After induction, sampling has continued until 4 hours 
(hourly 1 ml/h). The cell samples were precipitated 
by centrifugation (10000 ×g for 1 min), the 
supernatant was removed and protein preparation 
performed for each segment separately. The 
deposition procedure from the samples containing 
expressed protein in B. subtilis was performed by its 
saturation with NaCl and followed by centrifugation 
(10000 ×g for 10 min). Protein expression in each 
host was analyzed by SDS-PAGE and finally, 
western blot was performed to confirm expression of 
the intended protein in E. coli. 
Results 
Gel electrophoresis of the PCR products 
showed a 1 kDa band extracted from genome of 
influenza virus (H3N2) (similar to the HA sequence). 
Sequencing was confirmed accuracy of the HA1 
sequence cloned into pTZ57R/T vector. Also, colony 
PCR and restriction enzyme digestion was performed 
to confirm accuracy of pET-28a-HA1 and PHT43-
HA1. First, the restriction enzyme HindIII was used 
for simultaneous digestion of pET-28a and pET28a-
HA1. Since, this enzyme has restriction sites on both 
plasmid backbone and HA1, restriction enzyme 
digestion of  pET-28a-HA1using HindIII lead to the 
fragments about 600 bp and 5800 bp (Figure 1).  
Restriction enzyme analysis using SmaI and 
XbaI enzymes was also performed for simultaneous 
digestion of pHT43-HA1 and pHT43. As it be 
expected, using two above restriction enzymes, the 
fragments about 1010 bp and 8075bp came out after 
digestion of the recombinant vector; whereas, an 8036 
bp band was obtained after digestion of empty vector 
(Figure 2).  
 
 
Figure 1. Restriction enzyme digestion of pET-28a-HA1using HindIII. 





Figure 2. Restriction enzyme digestion of pHT43-HA1 and pHT43 
using restriction enzymes SmaI and XbaI. Two DNA fragments about 
1010 and 8075 obtained after pHT43-HA1 digestion (line 1) and only a 
DNA belt about 8075 gaind after digestion of pHT43 (line 2). 
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The SDS-PAGE results showed that 
expression of recombinant HA1 protein gradually 
increased until 4 hours after induction (42 kDa 
expressed protein in E.coli and 40 kDa expressed 
protein in Bacillus subtilis). Also, a 40 kDa protein 
band has been presented in deposited samples that 
confirm secretion of HA1 recombinant protein. The 
results also showed that the expressed protein band in 
E. coli has approximately 42 kDa in western blotting. 
Discussion 
One of the most important demands is the 
improvement of influenza vaccine to reach a more 
widespread and stable immune responses against the 
viruses. Recombinant vaccine technologies as new 
methods make easier to produce seasonal and 
pervasive vaccines (10). In recent decades, 
researchers are trying to produce efficient and safe 
vaccine that can be replaced for old ones. Different 





Figure 3. The SDS-PAGE results for evaluation of expression of recombinant HA1 protein in E.coli and Bacillus subtilis. A) line M: Prestained 
Protein Ladder (Sinaclon Cat. No. PR901641), line 1: Sample of fourth hour, line 2: Sample of third hour, line 3: Samples of second hour, line 4: 
Sample of first time, line 5: Sample before induction. B) line 1: Recombinant proteins secreted into the culture medium 16 hours after induction, line 
2: Lack of protein secretion in culture  medium before induction, line M: Prestained Protein Ladder (Sinaclon Cat. No. PR901641), line 3: Sample 




Figure 4. Detection of the recombinant HA1 protein by Western 
blot analysis using Anti-His6 monoclonal antibody; lane M, 
Prestained Protein Ladder (SinaClon Cat#PR901641) Lane 1, total 
cell protein sample of transformed E.Coli cells before IPTG 
induction; lane 2, the same sample 2h after IPTG induction, 
showing expected 42 kDa protein size; lane 3, A known His-
tagged protein sample weighed 36 kDa, used as positive control 
for WB procedure. 
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including insects and plants cells to express HA 
subtypes (11).  
Recent studies on spatial structure of 
hemagglutinin suggested that its globular region 
(HA1) is an appropriate option in production of 
recombinant vaccine (12). Since, HA1 alone possess 
most antigenic hemagglutinin properties that cause 
induction of the antibodies major neutralization 
responses against this glycoprotein, hence, HA1 gene 
was used to development of modern vaccines such as 
single unit vaccine, DNA based vaccine and virus 
like particle (13). For designing an effective and safe 
HA1- based vaccine, it is essential to cover inducer 
of  the production of neutralizing antibodies, the 
receptor binding domain (RBD) of H5N1 HA protein 
in HA1 subunit (14). RDB is the globular head of the 
HA1 subunit (1-320 amino acids). Khurana et al. 
(2011) in a study showed oligomers with defective 
function without addition of foreign oligomerization 
signal to the first five amino acids in the N terminus 
of HA1 in HA1 lacking amino acids 321 to 330 (15). 
In recent years, E. coli was applied widely in 
expression of recombinant proteins. In comparison 
with the other expression systems, E.coli is more 
suitable for continuous fermentation processes due to 
more rapid growth and its low cost (16). In other 
hand, expression system based on Bacillus subtilis 
possess some other suitable properties such as 
absence of codon biased, lack of mostly extracellular 
proteases and endotoxins, the ability to secrete 
soluble and active form of the protein into the 
medium and prevent to formation of inclusion bodies 
(17). In a similar study, it was confirmed that the 
globular region of hemagglutinin (binding region to 
receptor) which expressed in E. coli, as a 
recombinant protein, was concluded an immunogenic 
and protective response in mice (18). This protein 
can specifically bind to serum of infected individual 
with influenza virus. In the srudy by Farsad et al 
(2016), HA1-based vaccines was produced 
efficiently in bacterial systems with ability of large-
scale production in response to a pandemic influenza 
virus threat (19). 
In the study, data showed that the most 
production of recombinant HA1 protein in E. coli is 
four hours after induction and in Bacillus subtilis is  
16 hours after induction. Although we observed high 
speed production of the target protein in E. coli, but its 
expression in comparison with Bacillus subtilis was 
lower and more expensive, because expression system 
by using Bacillus subtilis don’t need to remove 
endotoxin and refolding process in order to obtain an 
active protein. According this research seems that the 
produced protein can be used for more evaluation of 
its immunogenicity in animal models as candidates for 
rapid and low-cost production of influenza vaccine 
against possible pandemic flu in the future.      
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